Oncotarget

Research Papers:

Cell cycle protein Bora serves as a novel poor prognostic factor in multiple adenocarcinomas

Qiong-Xia Zhang, Rui Gao, Jin Xiang, Zhong-Yu Yuan, Yuan-Min Qian, Min Yan, Zi-Feng Wang, Quentin Liu _, Hai-Dong Zhao and Chang-Hong Liu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:43838-43852. https://doi.org/10.18632/oncotarget.16631

Metrics: PDF 1683 views  |   HTML 2079 views  |   ?  


Abstract

Qiong-Xia Zhang1,2,*, Rui Gao1,*, Jin Xiang3, Zhong-Yu Yuan1, Yuan-Min Qian1,4, Min Yan1, Zi-Feng Wang1, Quentin Liu1, Hai-Dong Zhao1 and Chang-Hong Liu1

1Sun Yat-Sen University Cancer Center, The Second Affiliated Hospital, Dalian Medical University, Dalian 116044, China

2Department of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou 510060, China

3Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China

4Department of Gynecology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510060, China

*These authors have contributed equally to this work

Correspondence to:

Quentin Liu, email: [email protected]

Chang-Hong Liu, email: [email protected]

Hai-Dong Zhao, email: [email protected]

Keywords: Bora, prognosis, cancer, biomarker

Received: November 10, 2016     Accepted: February 28, 2017     Published: March 28, 2017

ABSTRACT

Cell cycle protein Bora has been identified to integrate the functions of three major mitotic kinases: Cyclin-dependent kinase-1, Polo-like kinase-1, and Aurora A kinase. Overexpression of Bora disrupts spindle assembly and causes genomic instability. However, the clinical relevance of Bora in cancer remains unclear. In this study, we examined the expression of Bora and its association with clinical characteristics in breast (n = 538), lung (n = 144) and gastric (n = 77) adenocarcinomas. We found that Bora was overexpressed in primary breast cancer tissues compared to paired non-cancerous tissues. Bora overexpression was observed at a higher proportion in triple-negative breast cancer (TNBC, 77.63%) compared with non-TNBC subtypes (42.76%, P < 0.0001). Kaplan-Meier survival analysis indicated that Bora overexpression was associated with unfavourable overall survival (OS, P < 0.0001) and disease-free survival (DFS, P = 0.007) in breast cancer. In addition, Bora subclassified patients with distinct clinical outcomes in both stages (II/III) and subtypes (HR+, HER2+) of breast cancer. Consistently, Bora was associated with adverse prognosis in lung (P = 0.005 for OS and DFS P = 0.001 for DFS) and gastric adenocarcinomas (P < 0.0001 for OS, and P < 0.0001 for DFS). Moreover, Bora was positively correlated with proliferation index Ki67 in breast and gastric cancer (P < 0.001, P = 0.005, respectively). Multivariate analyses further revealed that Bora was an independent prognostic parameter for OS and DFS in all three types of adenocarcinomas. In conclusion, our findings demonstrated that Bora was overexpressed and served as an independent biomarker for poor prognosis in multiple adenocarcinomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16631